SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:40:04 20/05/2024 pm IST			5-day change	1st Jan Change
42.86 ^USD	-4.40%		+3.07%	+16.99%

15/05	Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
02/05	Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	MT

SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 03, 2023 at 04:02 pm IST

SpringWorks Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 73.42 million compared to USD 61.8 million a year ago. Basic loss per share from continuing operations was USD 1.18 compared to USD 1.26 a year ago.

Latest news about SpringWorks Therapeutics, Inc.

Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM	15/05
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	02/05	MT
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	02/05	MT
Transcript : SpringWorks Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	02/05	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	12/03
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	06/03	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	06/03	MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	04/03	MT
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03	CI
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	27/02	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	27/02	MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating	26/02	MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating	07/02	MT
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	06/02	MT
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer	03/02	CI
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating	25/01	MT
Transcript : SpringWorks Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 07:30 AM	08/01
SpringWorks Therapeutics Closes $316.3 Million Common Stock Public Offering	09/12	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	05/12	MT
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	05/12	MT
SpringWorks Therapeutics Prices $275 Million Share Offering	05/12	MT
SpringWorks Therapeutics Launches $250 Million Public Offering of Shares; Stock Falls After Hours	05/12	MT

Chart SpringWorks Therapeutics, Inc.

Duration

Period

More charts

Company Profile

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract Number : 11520

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for SpringWorks Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.84 USD

Average target price

67.36 USD

Spread / Average Target

+50.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SPRINGWORKS THERAPEUTICS, INC.	+16.99%	331.99Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.68%	11TCr
ARGENX SE	-2.59%	2.2TCr
BIONTECH SE	-13.00%	2.19TCr
GENMAB A/S	-5.29%	1.92TCr
BEIGENE, LTD.	-3.69%	1.81TCr
WUXI APPTEC CO., LTD.	-38.57%	1.77TCr
NEUROCRINE BIOSCIENCES, INC.	+7.19%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+35.06%	1.24TCr

Bio Therapeutic Drugs